Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10303MR)

This product GTTS-WQ10303MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10303MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7532MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ269MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ674MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ1016MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ3452MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ14338MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ15558MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ7056MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW